Related Experiment Video
Updated: Aug 1, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
A Case Report on the Dramatic Response of 177Lu-PSMA Therapy for Metastatic Prostate Cancer
Aysenur Sinem Erdogan1, Haluk Sayan2, Bedri Seven3
1Department of Nuclear Medicine, Ankara City Hospital, University of Health Sciences, Ankara, Turkey.
Introduction:
In nuclear medicine, Prostate-specific Membrane Antigen (PSMA) is a potential target for theranostics. Offering superior diagnostic accuracy to conventional imaging in prostate cancer (PCa), Gallium-68 labeled PSMA (68Ga-PSMA) positron emission tomography/computed tomography (PET/CT) is considered the new standard of care in PCa management. Tumor cells identified as PSMA-avid on PET/CT imaging can be targeted and eliminated with PSMA-labeled Lutetium-177 (177Lu-PSMA) therapy.
Case Presentation:
A sixty-eight years old patient who had metastatic castration-resistant PCa was reported in this study. Prior to receiving 177Lu-PSMA therapy, the patient's PSA level was 358 ng/ml, and experienced extensive bone discomfort. Following ten cycles of 177Lu-PSMA therapy, exceptional results were observed.
Conclusion:
177Lu-PSMA therapy is likely to result in significantly better outcomes if first- or second-line treatments preserve the patient's bone marrow reserve or if the therapy is administered at earlier stages of the disease.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
09:49A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
